Greenwich LifeSciences Previews AACR Meeting with Key FLAMINGO-01 Data — Greenwich LifeSciences, Inc.

Event summary

Greenwich LifeSciences to present two abstracts and posters at AACR Meeting 2026 on April 20-21.
First statistically significant immune response data from FLAMINGO-01 Phase III trial to be revealed.
Non-HLA-A*02 arm of FLAMINGO-01 fully enrolled with 250 patients, showing 70-80% reduction in recurrence rate.
FLAMINGO-01 trial aims to detect a hazard ratio of 0.3 in invasive breast cancer-free survival.

The big picture

Greenwich LifeSciences is advancing its immunotherapy candidate GLSI-100 through a pivotal Phase III trial, aiming to prevent breast cancer recurrences. The upcoming AACR Meeting presentations will provide critical insights into the immune response and efficacy data from FLAMINGO-01, which could shape the future of HER2-targeted immunotherapies in oncology. With over 1,000 patients screened and promising preliminary results, the trial's success could validate a new approach to reducing metastatic breast cancer risk.

What we're watching

Clinical Efficacy: Whether the preliminary 70-80% reduction in recurrence rate in non-HLA-A*02 patients will be sustained through full trial completion.
Regulatory Pathway: The pace at which Greenwich LifeSciences can advance GLSI-100 toward regulatory approval based on FLAMINGO-01 results.
Market Positioning: How the differentiated immune response data will position GLSI-100 against existing HER2-targeted therapies in breast cancer treatment.